- Home
- STNG vs TNGX Comparison
STNG vs TNGX Comparison
Compare STNG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | TNGX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STNG | TNGX |
|---|---|---|
| Price | $74.70 | $26.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $83.33 | $21.78 |
| AVG Volume (30 Days) | 672.2K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $4.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $44.38 | $6.25 |
| 52 Week High | $87.39 | $34.39 |
Technical Indicators
Market Signals| Indicator | STNG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 47.23 |
| Support Level | $75.41 | $19.74 |
| Resistance Level | $81.66 | $28.41 |
| Average True Range (ATR) | 2.31 | 1.58 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 39.46 | 40.35 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.